Skystar Bio-Pharmaceutical Company  

(Public, OTCMKTS:SKBI)   Watch this stock  
Find more results for NASDAQ:SKBI
-0.030 (-5.36%)
Feb 5 - Close
OTCMKTS data delayed by 15 mins - Disclaimer
Currency in USD
Range 0.53 - 0.57
52 week 0.40 - 4.48
Open 0.57
Vol / Avg. 14,264.00/21,832.00
Mkt cap 4.61M
P/E 0.39
Div/yield     -
EPS 1.36
Shares 8.70M
Beta 1.76
Inst. own 20%

Key stats and ratios

Q3 (Sep '14) 2013
Net profit margin 26.75% 24.79%
Operating margin 29.42% 30.63%
EBITD margin - 34.67%
Return on average assets 12.00% 8.36%
Return on average equity 16.69% 10.19%
Employees 317 -
CDP Score - -


4/F, Building B, Chuangye Square No.48 Keji Road Gaoxin District
XI'AN, 710065
+86-29-88193188 (Phone)

Website links


Skystar Bio-Pharmaceutical Company (Skystar) is a holding company. The Company is engaged in the research, development, production, marketing, and sales of veterinary healthcare and medical care products. All of the Company’s operations are carried out by its subsidiaries in China and Xi’an Tianxing Bio-Pharmaceutical Co., Limited. It has four product lines: micro-organism products line, which include over 16 products; Veterinary medicine line for poultry and livestock, which includes over 145 products; Feed additives line, which includes over 16 products; and bio-pharmaceutical veterinary vaccine line, which includes over 10 products. The Company has approximately over 4000 customers in nearly 30 provinces in China.

Officers and directors

Weibing Lu Chairman of the Board, Chief Executive Officer
Age: 51
Bing Mei Chief Financial Officer
Age: 50
Wei Wen Secretary, Director
Age: 46
R. Scott Cramer Director
Age: 50
Mark D. Chen Independent Director
Age: 47
Qiang Fan Independent Director
Age: 58
Chengtun Qu Independent Director
Age: 48
Weirong Shen Independent Director
Age: 48